Literature DB >> 8554066

Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease.

L A Kluijtmans1, L P van den Heuvel, G H Boers, P Frosst, E M Stevens, B A van Oost, M den Heijer, F J Trijbels, R Rozen, H J Blom.   

Abstract

Mild hyperhomocysteinemia is an established risk factor for cardiovascular disease. Genetic aberrations in the cystathionine beta-synthase (CBS) and methylenetetrahydrofolate reductase (MTHFR) genes may account for reduced enzyme activities and elevated plasma homocysteine levels. In 15 unrelated Dutch patients with homozygous CBS deficiency, we observed the 833T-->C (I278T) mutation in 50% of the alleles. Very recently, we identified a common mutation (677C-->T; A-->V) in the MTHFR gene, which, in homozygous state, is responsible for the thermolabile phenotype and which is associated with decreased specific MTHRF activity and elevated homocysteine levels. We screened 60 cardiovascular patients and 111 controls for these two mutations, to determine whether these mutations are risk factors for premature cardiovascular disease. Heterozygosity for the 833T-->C mutation in the CBS gene was observed in one individual of the control group but was absent in patients with premature cardiovascular disease. Homozygosity for the 677C-->T mutation in the MTHFR gene was found in (15%) of 60 cardiovascular patients and in only 6 (approximately 5%) of 111 control individuals (odds ratio 3.1 [95% confidence interval 1.0-9.2]). Because of both the high prevalence of the 833T-->C mutation among homozygotes for CBS deficiency and its absence in 60 cardiovascular patients, we may conclude that heterozygosity for CBS deficiency does not appear to be involved in premature cardiovascular disease. However, a frequent homozygous mutation in the MTHFR gene is associated with a threefold increase in risk for premature cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8554066      PMCID: PMC1914961     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  31 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Three different methods for the determination of total homocysteine in plasma.

Authors:  M T te Poele-Pothoff; M van den Berg; D G Franken; G H Boers; C Jakobs; I F de Kroon; T K Eskes; J M Trijbels; H J Blom
Journal:  Ann Clin Biochem       Date:  1995-03       Impact factor: 2.057

3.  Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences?

Authors:  L Daly; K Robinson; K S Tan; I M Graham
Journal:  Q J Med       Date:  1993-10

4.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.

Authors:  P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

5.  Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?

Authors:  M den Heijer; H J Blom; W B Gerrits; F R Rosendaal; H L Haak; P W Wijermans; G M Bos
Journal:  Lancet       Date:  1995-04-08       Impact factor: 79.321

6.  Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency.

Authors:  P Goyette; P Frosst; D S Rosenblatt; R Rozen
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

7.  HOMOCYSTINURIA DUE TO CYSTATHIONINE SYNTHETASE DEFICIENCY: THE MODE OF INHERITANCE.

Authors:  J D FINKELSTEIN; S H MUDD; F IRREVERRE; L LASTER
Journal:  Science       Date:  1964-11-06       Impact factor: 47.728

8.  Two novel missense mutations in the cystathionine beta-synthase gene in homocystinuric patients.

Authors:  L A Kluijtmans; H J Blom; G H Boers; B A van Oost; F J Trijbels; L P van den Heuvel
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

9.  Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level.

Authors:  V Kozich; E Kraus; R de Franchis; B Fowler; G H Boers; I Graham; J P Kraus
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

10.  Human cystathionine beta-synthase cDNA: sequence, alternative splicing and expression in cultured cells.

Authors:  J P Kraus; K Le; M Swaroop; T Ohura; T Tahara; L E Rosenberg; M D Roper; V Kozich
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

View more
  88 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

Review 2.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

3.  Evaluation of GenoFlow Thrombophilia Array Test Kit in its detection of mutations in Factor V Leiden (G1691A), prothrombin G20210A, MTHFR C677T and A1298C in blood samples from 113 Turkish female patients.

Authors:  Ebru Aytekin; Sezen Guntekin Ergun; Mehmet Ali Ergun; Ferda E Percin
Journal:  Genet Test Mol Biomarkers       Date:  2014-08-25

4.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

Review 5.  Issues concerning the laboratory investigation of inherited thrombophilia.

Authors:  Armando Tripodi
Journal:  Mol Diagn       Date:  2005

6.  Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.

Authors:  D Caccamo; G Gorgone; M Currò; G Parisi; W Di Iorio; C Menichetti; V Belcastro; L Parnetti; A Rossi; F Pisani; R Ientile; P Calabresi
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 7.  Genetic association studies in osteonecrosis of the femoral head: mini review of the literature.

Authors:  Georgios Hadjigeorgiou; Efthimios Dardiotis; Maria Dardioti; Apostolos Karantanas; Apostolos Dimitroulias; Konstantinos Malizos
Journal:  Skeletal Radiol       Date:  2008-01       Impact factor: 2.199

8.  Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.

Authors:  A B Guttormsen; P M Ueland; I Nesthus; O Nygård; J Schneede; S E Vollset; H Refsum
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

9.  Elevated total plasma homocysteine and 677C-->T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease.

Authors:  R de Franchis; F P Mancini; A D'Angelo; G Sebastio; I Fermo; V de Stefano; M Margaglione; G Mazzola; G di Minno; G Andria
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

10.  The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease.

Authors:  Ozlem Kucukhuseyin; Ozlem Kurnaz; A Basak Akadam-Teker; Turgay Isbir; Zehra Bugra; Oguz Ozturk; Hulya Yilmaz-Aydogan
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.